A biobehavioral perspective on depressive symptoms in patients with cerebral astrocytoma.
|Article Type:||Clinical report|
Tumor necrosis factor (Health aspects)
Metastasis (Development and progression)
Metastasis (Risk factors)
Metastasis (Care and treatment)
Metastasis (Health aspects)
Cancer patients (Prognosis)
Cancer patients (Care and treatment)
Cancer patients (Health aspects)
Mental health (Health aspects)
Oncology, Experimental (Health aspects)
Highly active antiretroviral therapy (Health aspects)
Stress management (Health aspects)
Depression, Mental (Development and progression)
Depression, Mental (Risk factors)
Depression, Mental (Prognosis)
Depression, Mental (Care and treatment)
Depression, Mental (Health aspects)
Anxiety (Development and progression)
Anxiety (Risk factors)
Anxiety (Care and treatment)
Anxiety (Health aspects)
Family (Health aspects)
Intermediate filament proteins (Health aspects)
Gliomas (Development and progression)
Gliomas (Risk factors)
Gliomas (Care and treatment)
Gliomas (Health aspects)
Glutamate (Health aspects)
Cancer (Health aspects)
Cancer (Adjuvant treatment)
Starkweather, Angela R.
Lyon, Debra E.
McCain, Nancy L.
Bovbjerg, Dana H.
Broaddus, William C.
|Publication:||Name: Journal of Neuroscience Nursing Publisher: American Association of Neuroscience Nurses Audience: Professional Format: Magazine/Journal Subject: Health care industry Copyright: COPYRIGHT 2011 American Association of Neuroscience Nurses ISSN: 0888-0395|
|Issue:||Date: Feb, 2011 Source Volume: 43 Source Issue: 1|
|Topic:||Canadian Subject Form: Tumour necrosis factor; Tumour removal|
|Product:||Product Code: 8000421 Cancer Diagnosis; 8000220 Cancer & Cell R&D NAICS Code: 6215 Medical and Diagnostic Laboratories; 54171 Research and Development in the Physical, Engineering, and Life Sciences SIC Code: 8731 Commercial physical research; 8733 Noncommercial research organizations|
More than 51,000 individuals are diagnosed with a primary brain tumor in the United States each year, and for those with the most common type of malignant tumor, an astrocytoma, almost 75% will die within 5 years of diagnosis. Although surgery, radiation, and chemotherapy have improved length of survival, mortality remains high, which underscores the need to understand how other factors affect the disease trajectory. Several recent studies have shown that depressive symptoms are independently associated with reduced quality of life and survival time after controlling for other variables in patients with an astrocytoma. Thus, depressive symptoms represent a significant risk factor for adverse outcomes in this patient population. A growing body of evidence indicates that depressive symptoms are linked to underlying biological phenomena, particularly inflammatory activation modulated through increased peripheral levels of proinflammatory cytokines. Recent research has shown that neoplastic astrocytes respond to elevated proinflammatory cytokine levels by secreting immune mediators within the central nervous system, including cytokines and glial fibrillary acidic protein that promote astrogliosis and angiogenesis and may increase tumor growth and metastasis. However, because these biological factors have not as yet been measured in conjunction with depressive symptoms in these patients, little is known about the interactions that potentially influence the treatment trajectory. To guide future research and to provide a deeper understanding of the factors that may influence depressive symptoms and length of survival in patients with an astrocytoma, a review of the literature was undertaken. Publications over the past 10 years were analyzed to examine the theoretical models and measures of depressive symptoms used in previous research. Although numerous studies have documented the relationship between depression and reduced length of survival, there were several methodological concerns identified, and there were no studies that biological variables. Yet, research in the basic sciences provides compelling evidence of specific included neuroendocrine-immune interactions orchestrated by astrocytes that can cause depressive symptoms and alter the tumor microenvironment so that standard treatments are not as effective. These findings support the need for clinically based research so that we can begin to understand the potentially modifiable biobehavioral mechanisms underlying depressive symptoms in patients with an astrocytoma. Grounded in the biobehavioral research paradigm of psychoneuroimmunology, a novel research program is presented that may provide a new level of understanding regarding the high prevalence of depressive symptoms in patients with an astrocytoma and lead to new treatment strategies, with possible implications for improved symptom management and quality of life in patients with brain tumors.
Astrocytomas are a complex group of low- and high-grade tumors that comprise more than half of all primary brain tumors (Bondy et al., 2008). They are the most frequent cerebral tumor, with an incidence estimated at 1/12,500. Most patients diagnosed with an astrocytoma, regardless of the tumor grade, will not live beyond 5 years (Lin et al., 2002). Affecting primarily middle-aged adults, astrocytomas disrupt the lives of thousands of individuals and families each year as neurocognitive and functional status often deteriorate rapidly over the ensuing months. Besides the grade of astrocytoma, patient age and functional status remain the known preoperative prognostic indicators of survival (Lutterbach, Sauerbrei, & Guttenberg, 2003; McCarter et al., 2006). However, several recent studies have found that preoperative depressive symptoms are predictive of shorter survival time specifically among patients with an astrocytoma as opposed to other types of brain tumors (Gathinji et al., 2008; Litofsky et al., 2004; Mainio et al., 2006). Depressive symptoms have long been regarded as part of the normal emotional response to cancer diagnosis or a side effect of treatment (Gross, Smith, & Stem, 2007). Intriguing recent evidence, however, suggests that a biological pathway involving immune mediators may not only cause or worsen depressive symptoms but also may increase tumor treatment resistance (Litofsky & Resnick, 2009; Miller & Raison, 2008; Samaras et al., 2007). Although the grade of astrocytoma portends the disease trajectory and modalities of treatment, the proposed mechanisms underlying depressive symptoms may be present across grades because of the central role of astrocytes in regulating immune interactions within the central nervous system (CNS).
Epidemiological Overview of Astrocytoma
Astrocytomas represent 60% of all primary malignant brain tumors, and they are diagnosed in more than 24,000 people each year (American Cancer Society, 2007). Despite aggressive treatment, malignant astrocytomas cause more than 14,000 deaths annually. Astrocytomas are classified by tumor grade using the World Health Organization (WHO) system, which provides a prediction of their growth rate and ability to spread (Jemal et al., 2007). WHO grade I pilocytic astrocytomas and grade II diffuse astrocytomas are considered low grade, whereas the highly malignant forms, grade III anaplastic astrocytomas and grade IV glioblastoma multiforme (GBM), are high grade. The annual incidence of astrocytoma in the United States is 4 of every 100,000 people, with a male-to-female ratio of 3:2 (Central Brain Tumor Registry of the United States, 2008). Low-grade astrocytomas are more common in young adults, whereas high-grade astrocytomas primarily affect older adults. Caucasians are affected more often than any other race, and they occur more frequently in White non-Hispanics (American Cancer Society, 2007).
Pilocytic astrocytoma (WHO grade I) is a slow-growing cystic tumor occurring most often in young adulthood, with only a small portion (10%) located in the cerebral hemispheres (Jemal et al., 2007). Diffuse astrocytomas (WHO grade II), which include fibrillary astrocytoma, gemistocytic astrocytoma, and protoplasmic astrocytoma, affect primarily young adults and have a tendency for malignant progression to anaplastic astrocytoma and, ultimately, GBM. These tumors develop most commonly in the cerebrum and represent 35% of all astrocytic brain tumors. Anaplastic astrocytomas (WHO grade III) are most commonly located in the cerebral hemispheres and have a tendency to progress to GBM. The mean age at biopsy is approximately 41 years. GBM (WHO grade IV) is the most frequent malignant brain tumor, accounting for 15% of all brain tumors and 60% of all astrocytic tumors. The peak incidence occurs between the ages of 45 and 70 years, and these tumors are primarily found in the cerebral hemispheres (American Cancer Society, 2007).
Mean survival time varies by tumor grade, with the 5-year survival of grades I and II being 38% to 45%, respectively, whereas grade III is 29% and grade IV is 3% (Bondy et al., 2008). The median survival of patients with low-grade astrocytomas is 5 years, and most patients die from progression of their disease to a high-grade astrocytoma. The median survival for anaplastic astrocytoma is 3 years from time of diagnosis. Grade IV astrocytoma, GBM, is the most common type of glioma and has a survival time varying from less than 1 year to 3 years after initial diagnosis. Patients with a GBM usually have tumor recurrence, often within a year after completion of first-line therapy (Lin et al., 2002).
Although magnetic resonance imaging and positron emission tomography are used to provide a preliminary diagnosis, a biopsy must be performed to confirm diagnosis (Bondy et al., 2008). This typically occurs along with resection of the tumor. Tumor debulking or resection is the initial treatment for astrocytoma with the exception of tumors located in an area that would cause neurological devastation or when there is extensive metastasis (Claus & Black, 2006). Gross total resection has been associated with longer survival and improved neurological function (Brown et al., 2005). Surgery is followed by involved-field radiotherapy ranging from a total dose of 54 to 60 Gy, depending on tumor grade (Bondy et al., 2008). Adjuvant chemotherapy is not indicated for astrocytoma grades I to III but may be used to treat recurrent grade III tumors. Chemotherapy is typically used for grade IV astrocytomas, with temozolomide being the currently preferred agent because it is administered orally, has a favorable side effect profile, and is generally well tolerated by patients (Claus & Black, 2006). Unfortunately, despite advances in treatment modalities, little progress has been made in improving length of survival. Moreover, recent studies have shown that, regardless of the type and intensity of treatment, depressive symptoms are associated with shorter survival in patients with an astrocytoma (Gathinji et al., 2008; Litofsky et al., 2004; Mainio et al., 2005).
To guide future research and to provide a deeper understanding of the factors that may influence depressive symptoms and length of survival in patients with an astrocytoma, a review of the literature was undertaken. The questions of interest were the following: Is there an optimal theoretical model or framework used in prior studies that may inform future biobehavioral-based research? What methods or instruments have been used to measure depressive symptoms in patients with an astrocytoma? What other factors have been associated with depressive symptoms in previous research?
The following databases were used to obtain relevant research studies that address the questions of interest: CINAHL Plus, PsychINFO, OVID, and PubMed Central. The databases were searched for publications ranging from 1999 to 2009 using a combination of the following keywords or MeSH terms: brain neoplasms depression, depressive disorder, cytokines, and biological factors, with the following restrictions: English and research articles.
Results of the Literature Review
From the initial search, 18 articles were identified that measured depression or depressive symptoms in patients with a brain tumor. These publications were initially perused to inspect the study design and measurement of depressive symptoms. A more thorough examination was then conducted to identify the theoretical model of the study, the methods used to measure depressive symptoms, and other variables measured. The data from each article are listed in Table 1.
Theoretical Models of Previous Research
The theoretical model most often identified in the literature review was the biopsychosocial framework (Armstrong, Goldstein, Cohen, Jo, & Tallent, 2002; Arnold et al., 2008; Brown et al., 2006; Brown et al., 2005; D'Angelo et al., 2008; Davies, Hall, & Clarke, 2003; Giovagnoli, 1999; Giovagnoli, Silvani, Colombo, & Boiardi, 2005; Mainio et al., 2005, 2006; Wellisch, Kaleita, Freeman, Cloughesy, & Goldman, 2002). The remaining studies did not indicate or refer to a theoretical model when describing the study or in the discussion of the study results.
Methods Used to Measure Depressive Symptoms
Only one study included a diagnostic evaluation of depression by a neuropsychologist using major depressive disorder (MDD) criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Wellisch et al. (2002) evaluated depressive symptoms in 89 patients with a brain tumor, 70% of whom had an astrocytoma. Relevant symptoms of depression in these patients included energy loss, concentration problems, weight change, sadness, sleep disorder, motoric slowing, motivation loss/diminished interest in activities, guilt, and death ruminations. Six of the nine symptoms were reported by 50% or more of the patients. Of the sample, 28% were diagnosed with MDD by the neuropsychologist, indicating that this patient population was more than nine times more likely to have MDD than the general U.S. population.
Other studies used well-established screening instruments for depression, such as the Beck Depression Inventory (Armstrong et al., 2002; Hahn et al., 2003; Mainio et al., 2005, 2006; Pelletier, Verhoef, Khatri, & Hagen, 2002), the Multiphasic Personality Inventory-2 Depression (Armstrong et al., 2002), the Brief Patient Health Questionnaire (Arnold et al., 2008), the Hospital Anxiety and Depression Scale (Kilbride, Otellin, & Grigor'ev, 2007; Pringle, Taylor, & Whittle, 1999), and the Zung Self-rating Depression Scale (D'Angelo et al., 2008; Giovagnoli 1999; Giovagnoli et al., 2005). The remaining studies used mood assessment instruments, such as the Profile of Mood States, Short Form (Brown et al., 2005, 2006), the patient interviews (Davies et al., 2003), or the documentation of clinical depression in the patient's medical record by the physician or data suggestive of depression (Appleby, Appleby, & Rabin, 2008; Gathinji et al., 2008; Litofsky et al., 2004).
Other Factors That Influence Depressive Symptoms
Of the demographic variables measured, female gender (Armstrong et al., 2002; Arnold et al., 2008) and those with a lower educational level (Arnold et al., 2008) reported more symptoms of depression. A premorbid diagnosis of depression or diagnosis of active depression at the time of surgery were associated with more depressive symptoms in four studies (Appleby et al., 2008; Arnold et al., 2008; Gathinji et al., 2008; Kilbride et al., 2007). Tumor characteristics, such as lower grade (Arnold et al., 2008; Manio et al., 2005) or left hemisphere location (Armstrong et al., 2002; Hahn et al., 2003; Wellisch et al., 2002), were related to increased severity of depressive symptoms. The severity of other symptoms, including fatigue (Armstrong et al., 2002), cognitive impairment (Armstrong et al., 2002; Brown et al., 2006), and physical impairment (Brown et al., 2006; Davies et al., 2003; Giovagnoli, 1999; Giovagnoli et al., 2005), were found to increase depressive symptoms. Greater family support (Armstrong et al., 2002) and trait anxiety (D'Angelo et al., 2008; Giovagnoli, 1999) were found to be significantly related to depressive symptoms. And finally, a greater extent of surgery was related to decreased depressive symptoms in two studies (Brown et al., 2005; Gathinji et al., 2008) and increased depressive symptom in one study (Armstrong et al., 2002).
Theoretical Models of Previous Research
The literature review revealed that the biopsychosocial framework of depression was the most common theoretical model used in exploring the relationships among depressive symptoms and outcomes in patients with a cerebral tumor. This framework emphasizes the dynamic interactions among neurocognitive factors, psychological processes, and the social environment and is particularly useful for exploring the factors associated with depression. However, the biopsychosocial model does not incorporate the biological interactions occurring within the individual, which may modulate neurocognitive factors and psychological processes.
In addition, although most studies that used the biopsychosocial framework documented the tumor type or histology, the analyses did not appear to control for this variable, which may dilute the significance of tumor biology on depressive symptoms. For example, gliomas (e.g., astrocytomas, oligodendrogliomas, and ependymomas) may be associated with depressive symptoms because of the involvement of immunocompetent cells, whereas other types of primary brain tumors (e.g., meningiomas or acoustic neuromas) may not (Litofsky & Resnick, 2009). Two studies reported that the association between depressive symptoms and decreased length of survival was more evident in low-grade tumors (Arnold et al., 2008; Mainio et al., 2005), whereas two studies controlled for tumor type and grade in the inclusion criteria and analyses (Gathinji et al., 2008; Litofsky et al., 2004). Because tumor histology and grade may affect the production and release of biological factors that cause depressive symptoms, these variables should be included in the theoretical framework.
None of the research studies reviewed measured biological factors in conjunction with depressive symptoms in patients with a brain tumor. Yet, extensive research in psychiatry and other areas of health science have shown that biological factors can trigger the onset of depressive symptoms (Dantzer & Kelley, 2007; Kelley et al., 2003; Muller & Schwartz, 2007). Proinflammatory cytokines (particularly interleukin [IL]-I, IL-6, and tumor necrosis factor [alpha]), molecules involved in the initiation of the inflammatory response, cause or exacerbate depressive symptoms and activate astrocytes to release cytokines within the CNS (Raghavendra, Tanga, & DeLeo, 2004; Vollmer-Conna et al., 2004; Wichers & Maes, 2002).
Astrocytes are the major glial cell population within the CNS and act as immunocompetent cells; that is, they regulate local immune responses through the production and release of cytokines, such as IL-l, IL-6, and tumor necrosis factor ct (Dong & Benveniste, 2001). When the integrity of astrocytes is compromised, such as occurs with neoplasia, astrocytes also release glial acidic fibrillary protein (GFAP) into the CNS in addition to increased cytokines. GFAP is a Type III intermediate filament protein, the major protein component of the astrocyte cytoskeleton (Laping, Teter, Nichols, Rozorski, & Finch, 2008). Thus, GFAP serves as a biomarker of astrogliosis, and serum levels have been found to be highly correlated with astrocytoma volume (Brommeland, Rosengran, Fridland, Hennig, & Isaksen, 2007). Local levels of GFAP along with elevated cytokines have been implicated as driving factors in astrocytic differentiation and growth, angiogenesis, and astrogliosis and may alter the tumor microenvironment so that immune cells do not attack the tumor cells (Korzhevskii, Otellin, & Grigor'ev, 2005; Radeff Huang, Seasholtz, & Brown, 2005; Schneider, Sailer, Ansorge, Firsching, & Reinhold, 2006). Altered GFAP levels have also been described in postmortem samples of brain tissue from physically healthy individuals with MDD (Davis et al., 2002; Muguel-Hidalso et al., 2000). Because GFAP levels have been found to rise with tumor progression (Brommeland et al., 2007), the relationship to depressive symptoms warrants further exploration.
Although increased secretion of several specific cytokines from astrocytoma cells have been described, there is mounting evidence that cytokine patterns or the balance between pro- and anti-inflammatory cytokines may be more important than isolated, individual cytokine levels in understanding astrocytoma growth and resistance to treatment (Hao et al., 2002). Indeed, Samaras et al. (2007) recently compared levels of IL-6 and IL-10 in astrocytic neoplasms and in peripheral blood. They found that levels of both cytokines were higher in peripheral blood compared with healthy controls and that tumor and peripheral levels were highly correlated. The median IL-10 expression level by the neoplastic cells was significantly lower than that of IE-6, suggesting a localized cellular mechanism of immune suppression. Moreover, the principal IL-6-positive cell type was the neoplastic astrocyte, whereas microglial cells and macrophages appeared to be the major source of IE-10. Similarly, Kumar et al. (2006) documented significantly lower levels of serum IL-12 and higher levels of IL-10 among newly diagnosed patients with anaplastic astrocytoma and GBM. The authors concluded that astrocytomas cause a Th1/Th2 cytokine imbalance. Although these particular cytokines are implicated in regulating cell growth, resistance to chemotherapy, and angiogenesis (Liebrich et al., 2007), the possible involvement of other cytokines has yet to be determined.
Within the past few years, advances in technology have enabled a broad spectrum of cytokine measurements from a single specimen, which could be used to study pro- and anti-inflammatory cytokine interactions in the blood and tissue. Immunohistochemistry or genetic biomarkers may be used to identify the specific cytokine-releasing cells, providing a new level of understanding about the biological interactions that affect depressive symptoms, quality of life, and the disease trajectory.
[FIGURE 1 OMITTED]
To incorporate the possible multiple interactions among depressive symptoms, biological factors, and outcomes, the integrative paradigm of psychoneuroimmunology (PNI) could be used to guide a program of research in this area (Fox, Shepherd, & McCain, 1999; Starkweather, Witek-Janusek, & Mathews, 2005). PNI is a biobehavioral framework focused on the mechanisms of multidimensional psychobehavioral--neuroendocrine--immune system interactions that influence disease-specific outcomes (McCain, Gray, Walter, & Robins, 2005). Critical cofactors are viewed as moderators of neuroendocrine-immune (biological) interactions that potentially predispose the individual to depressive symptoms (see Figure 1). These may include personal characteristics (demographics, comorbidities, current symptoms, or social support), disease characteristics (tumor type and location), and treatment characteristics (extent of surgery, radiation, and chemotherapy). Neuroendocrine-immune interactions are central to the framework, denoting their importance in mediating states of health and disease. As noted earlier, for patients with an astrocytoma, specific biological factors have been implicated: glial fibrillary acidic protein, a biomarker of astrocytic activation, and local and circulating cytokines (Brommeland et al., 2007; Kumar et al., 2006; Liebrich et al., 2007; Samaras et al., 2007). Use of the PNI framework allows an examination of the psychosocial and biological factors affecting symptoms of depression and a method to develop hypotheses regarding the interactions that affect clinical outcomes.
Methods Used to Measure Depressive Symptoms
Although most, if not all, studies purported to be measuring depression, only one study included a diagnostic neuropsychological examination, the gold standard method of diagnosing clinical depression (Wellisch et al., 2002). In addition, there was a wide range of instruments used, with most relying on self-report questionnaires or chart review, making comparisons among studies impossible. Because of these discrepancies in the definition of depression and depressive symptoms, it remains unclear whether patients with clinical depression are at risk of decreased survival time or whether those who have a high severity of depressive symptoms but do not qualify as clinically depressed are also at risk.
Depressive symptoms include emotional, cognitive, and physical effects, and many symptoms overlap with those engendered by the disease process or as side effects of treatment in patients with an astrocytoma. Although the detrimental effects of clinical depression on health is well recognized, there remains controversy over the significance of depressive symptoms in this population because symptoms caused by the presence of an astrocytoma, such as fatigue and insomnia, may be part of their disease process (somatic symptoms) as opposed to an emotional aspect of depression (affective symptoms; Pasquini & Biondi, 2007). Thus, the measurement of depressive symptoms in patients with an astrocytoma may grossly overestimate the presence of clinical depression.
Recent opinions within the oncology literature, however, encourage the use of an inclusive approach toward identifying depressed individuals by counting the number of depressive symptoms, even if they may be disease or treatment related (Guo et al., 2006; Pasquini & Biondi, 2007; Reich, 2008). Much data demonstrate that subsyndromal depression is associated with significant subsequent morbidity in individuals both with and without cancer (Goodwin, Zhang, & Ostir, 2004; Myers, 2008). Likewise, depressive symptoms, even when not qualifying as clinical depression or MDD, are predictive of increased morbidity and mortality across a range of medical conditions (Hjerl et al., 2003; Lima et al., 2007).
The findings of Litofsky et al. (2004) underscore the need to understand the symptom manifestations of depression versus depressive symptoms, the effect of depression and/or depressive symptoms on the treatment trajectory, and the type of interventions that may be effective. In their prospective study of 598 patients with high-grade glioma, they found that whereas physicians reported depression in 15% of patients during the early postoperative period, 93% of patients reported symptoms consistent with depression. Symptoms of depression increased across the 6-month period after surgery and were associated with reduced quality of life scores. The length of survival was significantly shorter among patients with depression, even among those who received anti-depressant therapy, compared with patients who were not depressed.
These findings support the need to measure depressive symptoms and to include serial diagnostic neuropsychological evaluations over time so that we can begin to understand the differences between patients who experience clinical depression versus depressive symptoms. The measurement of biological factors may also provide insight on the associated mechanisms so that new treatment strategies can begin to be developed. For instance, proinflammatory cytokines can cause different behavioral features, including both a depressive syndrome, distinguished primarily by affective symptoms, and a neurovegetative syndrome characterized by somatic symptoms such as fatigue and loss of appetite (Anisman & Merali, 2003; Dantzer, 2006; Maletic et al., 2007; Miller & O'Callaghan, 2005; Reich, 2008). Although the depressive syndrome is typically responsive to antidepressants, the neurovegetative syndrome appears to be resistant to antidepressant treatment (Miller & Raison, 2008; Reich, 2008). Thus, antidepressants may provide only part of the solution to cytokine-associated behavioral disturbances.
Novel approaches to symptom management may include pharmacological agents that directly inhibit proinflammatory cytokines or enhance glucocorticoid signaling and inhibit inflammatory signaling (Chen et al., 2002). Biobehavioral nursing interventions may complement medical therapies. Mindfulness-based meditation has been shown to be an effective strategy for reducing depressive symptoms in patients with cancer and immune-based disease (McCain et al., 2003, 2008).
Other Factors That Influence Depressive Symptoms
Additional factors identified in the literature review that may influence depressive symptoms can be broadly categorized into patient characteristics (gender, educational level, premorbid diagnosis of depression, trait anxiety, current symptoms [fatigue, cognitive impairment, physical functioning], and family support], tumor characteristics (tumor grade and location), and treatment characteristics (extent of tumor resection). These factors were added into the proposed theoretical model developed by the authors, which will be used to guide future research in this area (Figure 1).
The literature review revealed several methodological concerns that should be addressed in future research. Most studies mixed tumor types into one sample, which could dilute the significance of the study findings for patients with an astrocytoma. The measurement of depression or depressive symptoms was inconsistent between studies, creating variability in how patients are categorized (as depressed or nondepressed). It would be helpful if researchers could agree to use one method or instrument to measure depression and/or depressive symptoms in future studies so that results can be compared and the effect of various treatment modalities between sites can be more fully examined.
The pervasive nature of depressive symptoms over the disease trajectory, the recent evidence indicating a relationship between depressive symptoms and reduced length of survival, and the research showing that astrocytes orchestrate local cytokine concentrations suggest a common biobehavioral mechanism underlying the presence of depressive symptoms in patients with an astrocytoma. The literature review supports the need to gain a better understanding of how neuroendocrine-immune interactions influence outcomes with the goal of facilitating the development of effective treatment strategies. An initial step of a possible program of research would be to determine the relationships among the depressive symptoms, the selected biological factors, and the patient-reported, functional, and treatment-related outcomes over time in patients with a cerebral astrocytoma. The relationship between cytokine and GFAP levels in tumor tissue and serum could be evaluated to determine whether systemic concentrations correlate with concentrations within the CNS. Although previous studies have shown that tumor tissue and serum levels of some individual cytokines are highly correlated, a PNI-based program of research would examine a broader range of both pro- and anti-inflammatory cytokines. Without a clear understanding of how inflammatory mediators affect somatic versus affective symptoms and clinical outcomes over time, there is a great risk that these patients will continue to suffer from a potentially treatable aspect of the disease process.
Characterization of the cytokine profile and the balance between pro- and anti-inflammatory cytokines over time should be established to determine how cytokine interactions affect depressive symptoms, astrocytoma growth and recurrence, and length of survival. Application of the PNI framework will provide an integrated perspective, enhancing the exploration of the multiple interactions among biological factors, depressive symptoms, and critical cofactors so that the effect on outcomes can be better understood. The results of such a program of research might potentially provide empirical evidence regarding the biological mechanisms underlying depressive symptoms, which may ultimately lead to better symptom management and more speculatively to reduced morbidity and mortality in patients with an astrocytoma.
DOI: 10.1097/J NN.0b013e3182029859
American Cancer Society. (2007). Cancer .facts and figures, 2007. Atlanta: Author. Retrieved August 30, 2007, from http://www.cancer.org/downloads/STT/CAFF2007PW Secured.pdf
Anisman, H., & Merali, Z. (2003). Cytokines, stress and depressive illness: Brain immune interactions. Annals of Medicine, 35, 2-11.
Appleby, B. S., Appleby, K. K., & Rabin, P. V. (2008). Predictors of depression and anxiety in patient with intracranial neoplasms. Journal of Neuropsychiatry and Clinical Neurosciences, 20, 447-449.
Armstrong, C. L., Goldstein, B., Cohen, B., Jo, M. Y., & Tallent, E. M. (2002). Clinical predictors of depression in patients with low-grade brain tumours: Consideration of a neurological versus a psychogenic model. Journal of Clinical Psychology in Medical Settings, 9, 97-107.
Arnold, S. D., Forman, L. M., Brigidi, B. D., Carter, K. E., Schweitzer, H. A., Quinn, H. E., et al. (2008). Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro-Oncology, 10, 171-181.
Bondy, M. L., Scheurer, M. E., Maimer, B., Barnholtz Sloan, J. S., Davis, F. G., & II'yasova, D. (2008). Brain tumor epidemiology: Consensus from the brain tumor epidemiology consortium. Cancer, 113, 1953-1968.
Brommeland, T., Rosengran, L., Fridland, S., Hennig, R., & Isaksen, V. (2007). Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurologica Scandinavica, 116, 380-384.
Brown, P. D., Ballman, K. V., Rummans, T. A., Maurer, M. J., Sloan, J. A., Boeve, B. F., et al. (2006). Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. Journal of Neuro-oncology, 76, 283-291.
Brown, P. D., Maurer, M. J., Rummans, T. A., Pollock, B. E., Ballman, K. V., Sloan, J. A., et al. (2005). A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: The impact of the extent of resection on quality of life and survival. Neurosurgery, 57, 495-504.
Central Brain Tumor Registry of the United States. (2008). Primary brain tumors in the United States: Statistical report 2005-2007 years data collected. Hinsdale, IL: Author.
Chen, T. C., Wasten, P., Su, S., Rawlinson, N., Hofman, F. M., Hill, C, K., et al. (2002). The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21 (Cip 1) and p27 (Kip 1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biology. and Therapy, 1, 268-276.
Claus, E. B., & Black, P. M. (2006). Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from SEER program, 1973-2001. Cancer, 15, 1358-1363.
D'Angelo, C., Mirijello, A., Leggio, L., Ferrulli, A., Carotenuto, V., Icolaro, N., et al. (2008). State and trait anxiety and depression in patients with primary brain tumors before and after surgery: 1-year longitudinal study. Journal of Neurosurgery, 108, 281-286.
Dantzer, R. (2006). Cytokines, sickness behavior and depression. Neurology Clinics, 24, 441-460.
Dantzer, R., & Kelley, K. W. (2007). Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity, 21, 153-160.
Davies, E., Hall, S., & Clarke, C. (2003). Two year survival after malignant cerebral glioma: Patients and relative reports of handicap, psychiatric symptoms and rehabilitation. Disability and Rehabilitation, 25, 259-266.
Davis, S., Thomas, A., Perry, R., Oakley, A., Kalaria, R. N., & O'Brien, J. T. (2002). Glial fibrillary acidic protein in late life major depressive disorder: An immunocytochemical study. Journal of Neurology, Neurosurgery, and Psychiatry, 73, 556-560.
Dong, Y., & Benveniste, E. N. (2001). Immune function of astrocytes. Glia, 36, 180-190.
Fox, S., Shephard, T. J., & McCain, N. (1999). Neurological mechanisms in psychoneuroimmunology. Journal of Neuroscience Nursing, 31, 87-96.
Gathinji, M., McGirt, M. J., Attenello, F. J., Chaichana, K. L., Than, K., Olivi, A., et al. (2008). Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surgical Neurology, 71, 299-303.
Giovagnoli, A. R. (1999). Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain turnout. Journal of Neurology, Neurosurgery, and Psychiatry, 67, 358-363.
Giovagnoli, A. R., Silvani, A., Colombo, E., & Boiardi, A. (2005). Facets and determinants of quality of life in patients with recurrent high grade gliomas. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 562-568.
Goodwin, J. S., Zhang, D. D., & Ostir, G. V. (2004). Effect of depression on diagnosis, treatment and survival of older women with breast cancer. Journal of the American Geriatrics Society, 52, 106-111.
Gross, A. F., Smith, F. A., & Stern, T. A. (2007). Is depression an appropriate response to having cancer? A discussion of diagnostic criteria and treatment decisions. Journal of Clinical Psychology, 9, 382-387.
Guo, Y., Musselman, D. L., Manatunga, A. K., Gilles, N., Lawson, K. C., Porter, M. R., et al. (2006). The diagnosis of major depression in patients with cancer: A comparative approach. Psychosomatics, 47, 376-384.
Hahn, C. A., Dunn, R. H., Logue, P. E., King, J. H., Edwards, C. L., & Halperin, E. C. (2003). Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. International Journal of Radiation Oncology, Biology, Physics, 55, 992-999.
Hao, C., Parney, I. F., Roa, W. H., Turner, J., Petruk, K. C., & Ramsay, D. A. (2002). Cytokines and cytokine receptor mRNA expression in human glioblasomas: Evidence of Thl, Th2 and Th3 cytokine dysregulation. Acta Neuropathologica, 103, 171-178.
Hjerl, K., Andersen, E. W., Keiding, N., Mouridsen, H. T., Mortenson, P. B., & Jorgensen, T. (2003). Depression as a prognostic factor for breast cancer mortality. Psychosomatics, 44, 24-30.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007). Cancer statistics, 2007. CA: A Cancer Journal for Clinicians, 57(1), 43-66.
Kelley, K. W., Bluthe, R. M., Dantzer, R., Zhou, J. H., Shen, W. H., Johnson, R. W., et al. (2003). Cytokine-induced sickness behaviors. Brain, Behavior, and Immunity, S1, S112-S118.
Kilbride, L., Smith, G., & Grant, R. (2007). The frequency and cause of anxiety and depression amongst patients with malignant brain tumours between surgery and radiotherapy. Journal of Neuro-Oncology, 84, 297-304.
Korzhevskii, D. E., Otellin, V. A., & Grigor'ev, I. P. (2005). Glial fibrillary acidic protein in astrocytes in the human neocortex. Neuroscience and Behavioral Physiology, 35, 789-792.
Kumar, R., Kamdar, D., Madden, L., Hills, C., Crooks, D., O'Brien, D., et al. (2006). Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncology Reports, 15, 1513-1516.
Laping, N. J., Teter, B., Nichols, N. R., Rozorski, I., & Finch, L. E. (2008). Glial fibrillary acidic protein: Regulation by hormones, cytokines, and growth factors. Brain Pathology, 4, 259-275.
Liebrich, M., Guo, L. H., Schluesener, H. J., Schwab, J. M., Dietz, K., & Will, B. E. (2007). Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Archivum Immunologiae et Therapiae Experimentalis, 55, 41-47.
Lima, V. P., Geller, J., Bangsberg, D. R., Patterson, T. L., Daniel, M., Kerr, T., et al. (2007). The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS, 21, 1175-1183.
Lin, C. L., Lieu, A. S., Lee, K. S., Yang, Y. H. C., Kuo, T. H., Hung, M. H., et al. (2002). The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surgical Neurology, 60, 402-406.
Litofsky, N. S., Farace, E., Anderson, F. Jr, Meyers, C. A., Huang, W., Laws, E. R. Jr, et al. (2004). Depression in patients with high-grade glioma: Results of the Glioma Outcomes Project. Neurosurgery, 54, 358-366.
Litofsky, N. S., & Resnick, A. G. (2009). The relationships between depression and brain tumors. Journal of NeuroOncology, 94, 153-161.
Lutterbach, J., Sauerbrei, W., & Guttenberg, R. (2003). Multivariate analysis of prognostic factors in patient with glioblastoma. Strahlentherapie und Onkologie, 1, 8-15.
Mainio, A., Hakko, H., Niemela, A., Koivukangas, J., & Rasanen, R (2006). Gender difference in relation to depression and quality of life among patients with a primary brain tumor. European Psychiatry, 21, 194-199.
Mainio, A., Tuunanen, S., Hakko, H., Timonen, M., Niemela, A., Koivukangas, J., & Rasanen, P. (2005). Depression in relation to survival among neurosurgical patients with a primary brain tumor: A 5-year follow-up study. Neurosurgery, 56, 1234-1241.
Maletic, V., Robinson, M., Oakes, T., Iyengar, S., Ball, S. G., & Russell, J. (2007). Neurobiology of depression: An integrated view of key findings. International Journal of Clinical Practice, 61, 2030-2040.
McCain, N. L., Gray, D. P., Elswick, R. K., Robins, J. W., Tuck, I., Walter, J. M., et al. (2008). A randomized clinical trial of alternative stress management interventions in persons with HIV infection. Journal of Consulting and Clinical Psychology, 76, 431-441.
McCain, N. L., Gray, D. P., Walter, J. M., & Robins, J. (2005). Implementing a comprehensive approach to the study of health dynamics using the psychoneuroimmunology paradigm. Advances in Nursing Science, 28, 320-332.
McCain, N. L., Munjas, B. A., Munro, C. L., Elswick, R. K., Robins, J. W., Ferreira-Gonzales, A., et al. (2003). Effects of stress management on PNI-based outcomes in persons with HIV disease. Research in Nursing and Health, 26, 102-117.
McCarter, H., Furlong, W., Whitton, A. C., Feeny, D., DePauw, S., Willan, A. R., et al. (2006). Health status measurements at diagnosis as predictors of survival among adults with brain tumors. Journal of Clinical Oncology, 24, 3636-3643.
Miller, A. H., & Raison, C. L. (2008). Immune system contributions to the pathophysiology of depression. Focus, 6, 36-45.
Miller, D. B., & O'Callaghan, J. P. (2005). Depression, cytokines and glial function. Metabolism: Clinical and Experimental, 54, S33-S38.
Muguel-Hidalso, J. J., Baucom, C., Dilley, G., Overholser, J. C., Meltzer, II. Y., Stockmeier, C. A., et al. (2000). Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biological Psychiatry, 48, 861-873.
Muller, N., & Schwarz, M. J. (2007). The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Molecular Psychiatry, 12, 988-1000.
Myers, S. (2008). Proinflammatory cytokines and sickness behavior: Implications for depression and cancer-related symptoms. Oncology Nursing Forum, 35, 802-807.
Osaba, D., Brada, M., Prados, M. D., & Yung, W. K. A. (2000). Effects of disease burden on health-related quality of life in patients with malignant gliomas. Neurooncology, 2, 221-228.
Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumour patients: The relative contributions of depression, fatigue, emotional distress, and existential issues. Journal of Neuro-Oncology, 57, 41-49.
Pasquini, M., & Biondi, M. (2007). Depression in cancer patients: A critical review. Clinical Practice and Epidemiology in Mental Health, 3, 1-9.
Pringle, A. M., Taylor, R., & Whittle, I. R. (1999). Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. British Journal of Neurosurgery, 13, 45-51.
Radeff Huang, J., Seasholtz, T. M., & Brown, J. H. (2005). Role of S1P signaling in TNF-alpha mediated astrocytoma cell proliferation. FASEB Journal, 19, A526-A527.
Raghavendra, V., Tanga, F. Y., & DeLeo, J. A. (2004). Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. European Journal of Neuroscience, 20, 467-473.
Reich, M. (2008). Depression and cancer: Recent data on clinical issues, research challenges and treatment approaches. Current Opinion in Oncology, 20, 353-359.
Samaras, V., Piperi, C., Korkolopoulou, P., Zisakis, A., Levidou, G., Themistocleous, M., et al. (2007). Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Molecular and Cellular Biochemistry, 304, 343-351.
Schneider, T., Sailer, M., Ansorge, S., Firsching, R., & Reinhold, D. (2006). Increased concentrations of transforming growth factor 131 and 132 in the plasma of patients with glioblastoma. Journal of Neuro-Oncology, 79, 61-65.
Starkweather, A. R., Witek-Janusek, L., & Mathews, H. L. (2005). Psychoneuroimmunology: An integrated research framework for neuroscience nurses. Journal of Neuroscience Nursing, 37, 56-61.
Vollmer-Conna, U., Fazou, C., Cameron, B., Li, H., Brennan, C., Luck, L., et al. (2004). Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behavior in humans. Psychological Medicine, 34, 1289-1297.
Wellisch, D. K., Kaleita, T. A., Freeman, D., Cloughesy, T., & Goldman, J. (2002). Predicting major depression in brain tumor patients. Psycho-Oncology, 11, 230-238.
Wichers, M., Maes, M. (2002). The psychoneuroimmuno-pathophysiology of cytokine induced depression in humans. International Journal of Neuropsychopharmacology, 5, 375-388.
Questions or comments about this article may be directed to Angela R. Starkweather, PhD MSN ACNP-BC CNRN, at astarkweathe@ vcu.edu. She is an assistant professor at the Virginia Commonwealth University School of Nursing, Richmond, VA.
Paula Sherwood, PhD RN CNRN, is an associate professor at the University of Pittsburgh School of Nursing, Pittsburgh, PA.
Debra E. Lyon, PhD RN FNP-BC, is an associate professor and a chair at the Department of Family and Community Health Nursing, Virginia Commonwealth University School of Nursing, Richmond, VA.
Nancy L. McCain, DSN RN FAAN, is a professor at the Virginia Commonwealth University School of Nursing, Richmond, VA. Dana Howard Bovbjerg, PhD, is director at the Biobehavioral Medicine in Oncology Program, and a visiting professor at the Departments of Psychiatry, Psychology, and Behavioral & Community Health Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
William C. Broaddus, MD PhD, is a professor at the Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA.
TABLE 1. Literature Review Findings Authors and Year of Study Design and Theoretical Publication Framework Factors Measured Appleby Retrospective review of Age, gender, race, marital et al. patients with primary or status, tumor type, (2008) metastatic brain tumors; location, and size, theoretical framework not premorbid psychiatric identified diagnoses, treatment modalities Armstrong Cross-sectional study of 57 Age, gender, marital et al. patients with low-grade status, hand dominance, (2002) brain tumors following fatigue, tumor type and surgery; biopsychosocial location, extent of framework surgery, cognitive function, vocational status, family support, psychological defenses, physical symptoms Arnold Cross-sectional study of Age, gender, marital et al. 363 patients with a primary status, ethnicity, (2008) brain tumor; education, tumor type, biopsychosocial framework grade, and site, previous psychiatric illness, anxiety, and depression Brown Longitudinal study of 194 Age, gender, previous et al. patients with high-grade radiotherapy, tumor grade, (2006) gliomas; biopsychosocial location, laterality, framework extent of resection, medication, cognitive function, physical function, fatigue, depression, and QOL Brown Longitudinal study of 124 Extent of surgery, et al. patients with high-grade medication, fatigue, (2005) gliomas before surgery and depression, QOL at 2 and 4 months postsurgery; biopsychosocial framework D'Angelo Longitudinal study of 72 Age, gender, tumor type, et al. patients with a primary location, and laterality, (2008) brain tumor before surgery anxiety, depression, and and at 1, 3, 6, and 12 cognitive impairment months postsurgery; biopsychosocial framework Davies Cross-sectional study of 12 Age, gender, functional et al. patients with a malignant status, work status, social (2003) brain tumor 24 months after activities, and surgery; biopsychosocial neuropsychological testing framework Gathinji Retrospective study of Age, gender, marital et al. 1,052 patients with status, tumor type, size, (2008) malignant astrocytoma (WHO location, and laterality grade III or IV); and treatment modalities theoretical framework not identified Giovagnoli Cross-sectional study of 57 Age, gender, marital (1999) patients with primary status, education, malignant brain tumor; cognitive functioning, biopsychosocial framework and work performance, QOL, tumor duration, type, and location Giovagnoli Cross-sectional study of 94 Age, gender, marital et al. patients with grades III to status, education, tumor (2005) IV anaplastic astrocytoma; grade and location, biopsychosocial framework cognition, physical performance, mood, and QOL Hahn et al. Cross-sectional study of 68 Age, education, tumor type, (2003) patients with a primary lateralization, size, brain tumor with no prior functional status, radiotherapy; theoretical neuropsychological testing, framework not identified and depression Kilbride Longitudinal study of 51 Age, gender, tumor site, et al. patients with primary laterality, grade, (2007) malignant brain tumor functional status, postsurgery, 3 weeks depression, and anxiety postsurgery, and preradiation treatment; biopsychosocial framework Litofsky Longitudinal study of 598 Age, gender, marital et al. patients with high-grade status, tumor grade, (2004) glioma before surgery and location, size, and 1, 3, and 6 months laterality and treatment postsurgery; theoretical modalities framework not identified Mainio Longitudinal study of 77 Age, gender, education, et al. patients with grades I-IV employment status, marital (2006) brain tumor before surgery status, premorbid and 3 and 12 months depression, tumor type, postsurgery; volume, and location, biopsychosocial framework functional performance, premorbid depression, and active depression Mainio Longitudinal study of 77 Age, gender, education, et al. patients with grades I-IV employment status, marital (2005) brain tumor before surgery status, premorbid and 3 and 12 months depression, tumor type, postsurgery; volume, and location, biopsychosocial framework functional performance, premorbid depression, and active depression Pelletier Cross-sectional study among Age, gender, marital et al. 73 patients with a primary status, education, tumor (2002) brain tumor; theoretical type, depression, fatigue, framework not identified emotional distress, existential well-being, and QOL Pringle Cross-sectional study of Age, gender, marital et al. 109 patients with an status, education, tumor (1999) intracranial neoplasm; type, location, and theoretical framework not laterality identified Wellisch Cross-sectional study of 89 Age, marital status, et al. patients with PMBT personal and family (2002) postsurgery or radiation; psychiatric history, tumor biopsychosocial framework location, neuropsychological testing, and self-reported symptoms Authors and Year of Publication Measurement of Depression Significant Findings Appleby Treating physicians' Depression and anxiety et al. diagnosis of depression and rates, as detected by (2008) anxiety or data in the physicians' assessment, chart that were suggestive were similar to the of either disorder 12-month prevalence rate in according to the DSM-IV the general population; the criteria most common correlate of reported depression and anxiety was a premorbid diagnosis of either disorder Armstrong BDI, MPI-2D After controlling for et al. fatigue, tumor location (2002) (posterior) and greater extent of surgery predicted a higher level of depression on MPI-2D; higher BDI scores were associated with female gender, greater fatigue, more cognitive impairment, and greater family support Arnold Brief Patient Health Female gender, lower tumor et al. Questionnaire grade, lower education (2008) level, and a history of psychiatric illness were predictors of symptoms consistent with anxiety and/ or depression Brown Profile of Mood States, QOL was positively et al. Short Form associated with cognitive (2006) and physical function but not demographic variables or tumor characteristics Brown Profile of Mood States, Patients who received et al. Short Form greater extent of surgery (2005) (gross total resection vs. subtotal resection or biopsy) had higher QOL and were less likely to experience worsening depression over time D'Angelo Zung Self-rating Depression A significant increase in et al. Scale, State-Trait Anxiety the number of patients with (2008) Inventory depression was found at 1 and 3 months postsurgery; a positive relationship between trait anxiety at enrollment and depression after surgery was found Davies Home-based interviews Patients with a lower level et al. of functioning were more (2003) likely to report symptoms of depression Gathinji Clinical diagnosis and Preoperative depression was et al. treatment by the primary associated with reduced (2008) provider or psychiatric length of survival; the physician difference in percent survival between the depressed and nondepressed cohorts was particularly evident at 12 months (15% vs. 41 %) and 20 months (0% vs. 21 %) Giovagnoli Zung Self-rating Depression Significant predictors of (1999) Scale, State-Trait Anxiety QOL included level of Scale depression and anxiety and daily and work performance Giovagnoli Zung Self-rating Depression QOL scores were et al. Scale, State-Trait Anxiety significantly related to (2005) Inventory greater cognition, physical performance, and mood Hahn et al. BDI Patients with left (2003) hemisphere tumors reported significantly more memory problems and depressive symptoms Kilbride HADS and unstructured HADS underestimated the et al. interviews presence of depression; (2007) patients who had suffered from depressive illness in the past were more likely to exhibit depression in the period between surgery and radiotherapy Litofsky Primary physician diagnosis Depressive symptoms were et al. using the DSM-IV criteria, associated with shorter (2004) patient report using the survival in patients with a SF-36 Mental Health score, glioblastoma (grade IV) but or a positive patient not for those with grade response to one of three III astrocytoma; mean questions related to survival time was depressive symptoms significantly shorter among patients identified as depressed (34.0 weeks) compared with those who were identified as nondepressed by their physician (41.1 weeks) Mainio Premorbid depression After controlling for et al. measured with the demographic f variables, (2006) Crown-Crisp Experiential preinjury depression, and Index, active depression tumor characteristics, the measured with BDI level of depression predicted QOL at all treatment time intervals Mainio Premorbid depression A BDI score >10 was et al. measured with the significantly related to (2005) Crown-Crisp Experiential decreased survival time in Index, active, and low-grade gliomas but not depression measured with in high grade gliomas; BDI patients with a preoperative BDI <10 or with a previous lifetime history of depression had a significantly longer survival time r than those with higher preoperative depressive symptoms (60 vs. 51.7 months) Pelletier BDI-II Of the sample, 38% had a et al. BDI-II score in the (2002) clinically depressed range; the presence of depressive symptoms was the single most important independent predictor of QOL Pringle HADS Anxiety was reported by 30% et al. and depression by 16% of (1999) patients; findings were not significantly different than other surgical groups Wellisch MDD diagnosed by structured Significant predictors of et al. psychiatric interview using MDD included frontal (2002) the DSM-IV criteria location of tumor, sadness and lack of motivation symptoms, and family psychiatric history Note. DSM-IV= Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; BDI = Beck Depression Inventory; MPI- 2D = Multiphasic Personality Inventory-2 Depression; QOL = quality of life; WHO = World Health Organization; HADS = Hospital Anxiety and Depression Scale; PMBT = primary malignant brain tumor; MDD = major depressive disorder.
|Gale Copyright:||Copyright 2011 Gale, Cengage Learning. All rights reserved.|